Showing results (261-270 of 314) with videos related to

Sort By:
Pageof 32
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry AnalysisDavid C Chen, James P Buteau, Nathan Papa, et al.
The Prostate|June 19, 2019
Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancerLaura H Porter, Mitchell G Lawrence, Hong Wang, et al.
European Urology|May 8, 2021
A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate CancerThomas Van den Broeck, Daniela Oprea-Lager, Lisa Moris, et al.
European Urology|November 5, 2023
Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in UrologyMichael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al.
European Urology Oncology|June 13, 2022
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand TherapyStefano Fanti, Alberto Briganti, Louise Emmett, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
The Journal of Urology|April 28, 2025
Pelvic Lymph Node Dissection in Prostate Cancer: Is It Really Necessary? A Multicentric Longitudinal Study Assessing Oncological Outcomes in Patients With Prostate Cancer Patients Undergoing Pelvic Lymph Node Dissection vs Radical Prostatectomy OnlyMarc A Furrer, Niranjan J Sathianathen, Clancy J Mulholland, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
The Lancet. Oncology|September 18, 2024
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyArun A Azad, Mathias Bressel, Hsiang Tan, et al.
European Urology Oncology|May 7, 2025
Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate CancerJianliang Liu, Laurence Harewood, Dominic Bagguley, et al.
Pageof 32